Wedbush Maintains Outperform on Alpine Immune Sciences, Raises Price Target to $19
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Robert Driscoll maintains an Outperform rating on Alpine Immune Sciences (NASDAQ:ALPN) and raises the price target from $17 to $19.
August 15, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst maintains Outperform rating on Alpine Immune Sciences and raises the price target from $17 to $19.
The news of an analyst maintaining an Outperform rating and raising the price target typically indicates a positive outlook for the company. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100